Alternative Pain Relief: The Rise of Akuamma Seed in America

Akuamma Seed (Picralima nitida) Use in the U.S.: Findings from a Web-Based Survey.

Journal of psychoactive drugs β€’ β€’ Moderately Relevant
πŸ€–

AI Summary

A recent web-based survey has shed light on the emerging use of Picralima nitida (akuamma seed), a traditional West African botanical with potential pain management properties. Out of 369 participants, only 7.6% (28 individuals) reported lifetime use of akuamma seed, revealing it as a relatively niche alternative substance in the United States. The study uncovered interesting demographic patterns, showing that users tend to be older females, often with disabilities, who are exploring alternative pain management strategies.

The research highlights a fascinating intersection between botanical substances and pain management. Users reported significant pain relief (60.7%) from akuamma seed, with motivations primarily focused on pain management and potential opioid substitution. Interestingly, the survey found a strong correlation between akuamma seed users and consumption of other unscheduled psychoactive substances, including 71.4% using Delta-8 THC and 100% having tried kratom. This suggests a broader trend of individuals seeking alternative botanical approaches to pain and wellness.

Despite these intriguing findings, researchers emphasize the need for additional scientific investigation to evaluate the safety, efficacy, and long-term health outcomes associated with akuamma seed use. The study provides an important preliminary look into an understudied botanical, highlighting the complex landscape of alternative pain management strategies in the United States.

πŸ“„ Original Abstract

Indigenous to West Africa, akuamma seed (Picralima nitida) is used in traditional medicine and demonstrates opioidergic activity. Little is known about its role in management of pain or other ailments among people in the United States. This study presents findings from a web-based survey conducted between December 2023 and July 2024. Summary statistics characterized individuals reporting lifetime akuamma seed use, including demographics, substance use history, pain severity, and motivations. Between-group comparisons were conducted for those with and without lifetime akuamma seed use. Among 369 participants, 28 (7.6%) reported lifetime akuamma seed use. Those with lifetime akuamma seed use were older (44.7 years, p = .04), females (64.3%, p = .004), or currently disabled (32.1%, p < .001). They reported less alcohol (p = .033), more kava (78.6%, p = .001) and Delta-8 THC (71.4%, p < .001) use; all had tried kratom. Those who had tried akuamma seed indicated greater pain severity and reported use for pain management and opioid substitution; 60.7% reported pain relief from akuamma seed. No participants met DSM-5 criteria for akuamma seed-related substance use disorder modified. Akuamma seed may be used in the United States alongside other unscheduled psychoactive substances, particularly, psychoactive botanical-derived products. Additional research is needed to evaluate safety, efficacy, and health outcomes associated with akuamma seed.

Explore More Research

Stay informed about the latest cannabis science.

Your stash, decoded.